About the Authors

Jose A. Crespo

Affiliation Experimental Psychiatry Unit, Department of General Psychiatry and Social Psychiatry, Innsbruck Medical University, Innsbruck, Austria

Petra Stöckl

Affiliation Experimental Psychiatry Unit, Department of General Psychiatry and Social Psychiatry, Innsbruck Medical University, Innsbruck, Austria

Florian Ueberall

Affiliation Innsbruck Biocentre, Division of Medical Biochemistry, Innsbruck Medical University, Innsbruck, Austria

Marcel Jenny

Affiliation Innsbruck Biocentre, Division of Medical Biochemistry, Innsbruck Medical University, Innsbruck, Austria

Alois Saria

Affiliation Experimental Psychiatry Unit, Department of General Psychiatry and Social Psychiatry, Innsbruck Medical University, Innsbruck, Austria

Gerald Zernig

gerald.zernig@i-med.ac.at

Affiliation Experimental Psychiatry Unit, Department of General Psychiatry and Social Psychiatry, Innsbruck Medical University, Innsbruck, Austria

Competing Interests

Dr Gerald Zernig has received speaker's or consultancy fees or unrestricted educational grants or support for the execution of scientific conferences from the following pharmaceutical companies (in alphabetical order) which are manufacturers of antidepressants, antipsychotics, analgesics, opioid substitution medications, and/or hypnotics: AlcaSynn, AstraZeneca, Bio-Rad, Bristol-Myers Squibb, Eli Lilly, Kwizda, Janssen, Lundbeck, Mundipharma, Novartis, Nycomed, Pfizer, and Wyeth. He has held compensated yet unrestricted lectures on problems of therapeutic drug monitoring (TDM) for (in alphabetical order) the following pharmaceutical companies: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck, and Pfizer. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: JAC GZ. Performed the experiments: JAC PS MJ. Analyzed the data: JAC. Contributed reagents/materials/analysis tools: MJ FU AS. Wrote the paper: GZ.